Search results for " Varicella"

showing 10 items of 13 documents

Vaccination and Vaccine Effectiveness: A Commentary of Special Issue Editors

2020

The Special Issue “Vaccination and Vaccine Effectiveness”, published in the journal Vaccines, has the main aim to increase international literature data on vaccine effectiveness and safety and on vaccination strategies in order to reduce vaccine hesitancy and improve vaccination coverage rates. The main topics included in the call for papers were vaccines administered to infants, adolescents, adults, elderly people, at-risk populations (due to comorbidities and personal risk factors) and healthcare workers and strategies adopted to promote vaccination adherence among these categories. This Special Issue started from the assumption that, despite vaccination being universally recognized as on…

0301 basic medicinemedicine.medical_specialtyImmunologyPopulationlcsh:MedicineRubella and varicella vaccinationVaccines AdministeredMeasles03 medical and health sciences0302 clinical medicineQuality of life (healthcare)Internationally adopted childrenDrug DiscoveryHealth caremedicinemeaslesElderly peoplePharmacology (medical)Research article030212 general & internal medicinehepatitis B vaccinationeducationPharmacologyHuman papillomavirus vaccinationeducation.field_of_studyvaccine effectivenesshealthcare workersbusiness.industrylcsh:Rvaccinationmedicine.diseaseinfluenza vaccinationVaccinationEditorial030104 developmental biologyInfectious DiseasesFamily medicineHealthcare workervaccine hesitancymumpsHerpes zoster vaccinationbusinessVaccines
researchProduct

The impact of ten years of infant universal Varicella vaccination in Sicily, Italy (2003-2012).

2015

Introduction Universal varicella vaccination in Sicily was introduced in infant population since 2003, with a rapidly increasing coverage. Aim of the present study was to analyze changes in the epidemiology of varicella since the introduction of universal vaccination. Methods The study was performed by analyzing Sicilian administrative/clinical data on varicella case notifications and hospitalizations from 2003 to 2012 (ICD-9-CM discharge diagnosis codes 052 and 052.×). MMR+V and V coverage were also calculated for each birth cohort. Moreover, blood samples drawn in 2013/2014 from general population stratified by age were tested for varicella antibodies. Results From 2003 to 2012, 15 433 va…

AdultMalePediatricsmedicine.medical_specialtyAdolescentImmunologyPopulationSocio-culturalecoverageVaricella vaccinationAntibodies ViralSettore MED/42 - Igiene Generale E ApplicataChickenpox VaccineYoung AdultChickenpoxvaricellaEpidemiologyHumansImmunology and AllergyMedicineYoung adultChildeducationDisease NotificationSicilyChickenpox VaccineHospitalizationsPharmacologyeducation.field_of_studyChickenpoxbusiness.industryVaccinationInfant NewbornInfantNotificationsmedicine.diseaseHospitalizationVaccinationCoverage; Epidemiology; Hospitalizations; Notifications; Sicily; Universal mass vaccination; VaricellaChild PreschoolFemaleepidemiologynotificationbusinessBirth cohortuniversal mass vaccinationHumanResearch Paperhospitalization
researchProduct

Atypical presentation of ramsay hunt syndrome without facial palsy in an immunocompetent young male

2013

Antiviral-steroid therapy; Immunocompetent; Ramsay hunt syndrome; Varicella zoster virus; Young; Medicine (all)Varicella zoster virusMedicine (all)Antiviral-steroid therapyYoungRamsay hunt syndrome; Antiviral-steroid therapy; ImmunocompetentRamsay Hunt syndrome Varicella Zoster Virus immunocompetent young antiviral-steroid therapy.ImmunocompetentRamsay hunt syndrome
researchProduct

Coverage, efficacy or dosing interval: which factor predominantly influences the impact of routine childhood vaccination for the prevention of varice…

2016

Background Varicella is a highly infectious disease with a significant public health and economic burden, which can be prevented with childhood routine varicella vaccination. Vaccination strategies differ by country. Some factors are known to play an important role (number of doses, coverage, dosing interval, efficacy and catch-up programmes), however, their relative impact on the reduction of varicella in the population remains unclear. This paper aims to help policy makers prioritise the critical factors to achieve the most successful vaccination programme with the available budget. Methods Scenarios assessed the impact of different vaccination strategies on reduction of varicella disease…

Budgets0301 basic medicineMalePediatricsNational Health ProgramsNational Health ProgramDiseaseVaricella0302 clinical medicineChickenpoxEpidemiology030212 general & internal medicineChildChickenpox Vaccineeducation.field_of_studyChickenpoxlcsh:Public aspects of medicineImmunization ProgramVaccinationvirus diseasesCoverage; Dosing interval; Efficacy; Routine varicella vaccination impact; VaricellaVaccinationItalyBudgetDosing intervalFemalePublic HealthResearch ArticleHumanmedicine.medical_specialtyCoverageAdolescentEfficacy030106 microbiologyPopulationSocio-culturaleVaccines AttenuatedMass VaccinationRoutine varicella vaccination impactChickenpox Vaccine03 medical and health sciencesCoverage; Dosing interval; Efficacy; Routine varicella vaccination impact; Varicella; Public Health Environmental and Occupational HealthmedicineHumansDosingeducationImmunization Programsbusiness.industryEnvironmental and Occupational HealthPublic Health Environmental and Occupational Healthlcsh:RA1-1270Models Theoreticalmedicine.diseaseVaccine efficacybusinessBMC Public Health
researchProduct

Updated insights into the mechanism of action and clinical profile of the immunoadjuvant QS-21: A review

2019

Background Vaccine adjuvants are compounds that significantly enhance/prolong the immune response to a co-administered antigen. The limitations of the use of aluminium salts that are unable to elicite cell responses against intracellular pathogens such as those causing malaria, tuberculosis, or AIDS, have driven the development of new alternative adjuvants such as QS-21, a triterpene saponin purified from Quillaja saponaria. Purpose The aim of this review is to attempt to clarify the mechanism of action of QS-21 through either receptors or signaling pathways in vitro and in vivo with special emphasis on the co-administration with other immunostimulants in new adjuvant formulations, called a…

InflammasomesT-Lymphocytesmedicine.medical_treatmentHerpes zosterPharmaceutical ScienceMonophosphoryl Lipid AAPCs antigen presenting cellsMiceCMI cell mediated immunity0302 clinical medicineDrug DiscoveryHerpes Zoster VaccineMedicineNSCLC non small cell lung carcinomaCancerImmunity CellularVaccines Synthetic0303 health sciencesImmunogenicityIl-2 interleukine 2HIV human immunodeficiency virusLipid A030220 oncology & carcinogenesisCytokinesMolecular MedicineDCs dendritic cellsNK natural killerAdjuvantTLR Toll-like receptorHerpes Zoster VaccineCD cluster of differentiationAntigen-Presenting CellsCTL cytotoxic T lymphocytesHZ herpes zosterMPL 3-deacylated monophosphoryl lipidVaccine adjuvantImmunoadjuvantArticleVZV varicella zoster virus03 medical and health sciencesImmune systemAdjuvants ImmunologicAntigenPAMPs pathogen-associated molecular patternsMalaria VaccinesPRRs pathogen recognition receptorsQS-21 Quillaja saponaria Molina-fraction 21AnimalsMHC major histocompatibility complexMtb Mycobacterium tuberculosis bacteriaSARS severe acute respiratory syndromeAntigen-presenting cellIFN-γ interferon-gamma030304 developmental biologyPharmacologybusiness.industryA-β amyloid-betaTNF-α tumor necrosis factor-alphaSaponinsQS-21MalariaQuillaja saponariaComplementary and alternative medicineTCR T-cell receptorLiposomesImmunologyKLH keyhole limpet hemocyaninbusinessdLN draining lymph nodesMAPK mitogen activated protein kinasePhytomedicine
researchProduct

Has VZV epidemiology changed in Italy? Results of a seroprevalence study

2017

The aim of the study was to evaluate if and how varicella prevalence has changed in Italy. In particular a seroprevalence study was performed, comparing it to similar surveys conducted in pre-immunization era. During 2013–2014, sera obtained from blood samples taken for diagnostic purposes or routine investigations were collected in collaboration with at least one laboratory/center for each region, following the approval of the Ethics Committee. Data were stratified by sex and age. All samples were processed in a national reference laboratory by an immunoassay with high sensitivity and specificity. Statutory notifications, national hospital discharge database and mortality data related to V…

Male0301 basic medicinePediatricsCross-sectional studySeroprevalenceSettore MED/42 - Igiene Generale E ApplicataAntibodies Viralmedicine.disease_causeChickenpox0302 clinical medicineChickenpox; Immunization; Seroprevalence; Surveillance; Varicella-Zoster Virus; Adolescent; Adult; Age Factors; Aged; Aged 80 and over; Antibodies Viral; Chickenpox; Child; Child Preschool; Cross-Sectional Studies; Female; Humans; Infant; Infant Newborn; Italy; Male; Middle Aged; Seroepidemiologic Studies; Young Adult; Immunology and Allergy; Immunology; PharmacologySeroepidemiologic StudiesEpidemiology80 and overImmunology and AllergyAge FactorViral030212 general & internal medicineYoung adultChildskin and connective tissue diseasesAged 80 and overSurveillanceChickenpoxVaricella-Zoster ViruAge FactorsMiddle AgedResearch PapersItalyChild PreschoolFemaleChickenpox; Immunization; Seroprevalence; Surveillance; Varicella-Zoster Virus; Immunology and Allergy; Immunology; PharmacologyHumanAdultmedicine.medical_specialtyAdolescent030106 microbiologyImmunologyAntibodiesNOYoung Adult03 medical and health sciencesChickenpox; Immunization; Seroprevalence; Surveillance; Varicella-Zoster VirusmedicineHumansSeroprevalencePreschoolAgedCross-Sectional StudiePharmacologybusiness.industrySeroepidemiologic StudieInfant NewbornVaricella zoster virusInfantSeroepidemiologic StudiesNewbornmedicine.diseaseVaricella-Zoster VirusCross-Sectional StudiesImmunizationImmunizationsense organsChickenpox Immunization Seroprevalence Surveillance Varicella-Zoster Virus Immunology and Allergy Immunology Pharmacologybusiness
researchProduct

Impact of universal vaccination against varicella in Italy.

2014

In Italy, the introduction of Universal Varicella Vaccination (UVV) has been decided but postponed, as a national programme, until 2015, when data from Regions which have already implemented it will be available. Starting from 2003, eight Italian Regions (Basilicata, Calabria, Friuli Venezia Giulia, Apulia, Sardinia, Sicily, Tuscany and Veneto) have progressively introduced UVV, in their immunization programme, with different schedules in children aged 13–15 months and 5–6 years, currently a two-dose schedule is adopted by all Regions. In June 2013, an Interregional Group on Varicella Vaccination (IGVV) has been established in order to assess the effectiveness of varicella vaccination with …

MaleImmunization ProgramsHealth PolicyIncidenceimmunization coverageVaccinationUniversal Varicella VaccinationInfantnotificationsadverse events following varicella immunizationVaricellaChickenpox VaccineHospitalizationChickenpoxItalyChild PreschoolHumansFemaleHealth Services ResearchChildhospitalizationsResearch PaperHuman vaccinesimmunotherapeutics
researchProduct

Severe complications of varicella in previously healthy children in Germany: a 1-year survey.

2001

Objective.Varicella is a common infectious disease, usually benign and self-limited, and complications are believed to be rare. The purpose of this study was to describe the epidemiology of severe varicella complications in immunologically healthy children in Germany.Methods.Information on any admission of children with a severe complication associated with chickenpox was solicited throughout 1997 from all 485 pediatric hospitals in Germany using an established surveillance system. The case definition included nonimmunocompromised individuals who were up to 16 years of age and hospitalized with neurologic complications, bacterial superinfections, or hematologic complications.Results.The res…

Malemedicine.medical_specialtyPediatricsAdolescentPopulationAge DistributionChickenpoxGermanyEpidemiologyMedicineHumansProspective StudiesSkin Diseases InfectiouseducationFasciitisChildEncephalitis Varicella Zostereducation.field_of_studyChickenpoxbusiness.industryOsteomyelitisInfant NewbornInfantmedicine.diseaseMeningitis ViralCellulitisChild PreschoolPopulation SurveillancePediatrics Perinatology and Child HealthFemaleSeasonsOrbital cellulitisbusinessMeningitisPediatrics
researchProduct

Immunogenicity and safety of two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children.

2006

Combination vaccines against common childhood diseases are widely used, provide an improved coverage, are more convenient and are more cost-effective than multiple injections. We conducted a study to evaluate the safety and immunogenicity of a combined measles-mumps-rubella-varicella (MMRV) candidate vaccine in comparison with the separate administration of licensed measles-mumps-rubella (MMR; Priorix) and varicella (V; Varilrix) vaccines.Healthy children 12-18 months of age received 2 doses of MMRV vaccine (3 lots) 6-8 weeks apart (MMRV group) or 1 dose of MMR vaccine administered concomitantly with 1 dose of varicella vaccine, followed by a second dose of MMR at 6-8 weeks later (MMR+V gro…

Microbiology (medical)MaleHerpesvirus 3 HumanFeverPainHyperemiamedicine.vaccineAntibodies ViralRubellaMeaslesCombination vaccinesChickenpox VaccinemedicineHumansVaccines CombinedMeasles mumps rubella varicellaMMRV vaccinebusiness.industryImmunogenicityvirus diseasesInfantmedicine.diseaseInfectious DiseasesMumps virusMeasles virusImmunoglobulin GPediatrics Perinatology and Child HealthImmunologyFemaleViral diseasebusinessMeasles-Mumps-Rubella VaccineThe Pediatric infectious disease journal
researchProduct

Impact of universal vaccination against varicella in Italy: Experiences from eight Italian Regions.

2014

In Italy, the introduction of Universal Varicella Vaccination (UVV) has been decided but postponed, as a national programme, until 2015, when data from Regions which have already implemented it will be available. Starting from 2003, eight Italian Regions (Basilicata, Calabria, Friuli Venezia Giulia, Apulia, Sardinia, Sicily, Tuscany and Veneto) have progressively introduced UVV, in their immunization programme, with different schedules in children aged 13-15 months and 5-6 years, currently a two-dose schedule is adopted by all Regions. In June 2013, an Interregional Group on Varicella Vaccination (IGVV) has been established in order to assess the effectiveness of varicella vaccination with …

Pediatricsmedicine.medical_specialtyImmunologyadverse events following varicella immunizationVaricellaSettore MED/42 - Igiene Generale E ApplicataEnvironmental healthmedicineImmunology and AllergyHealth policyChickenpox VaccinePharmacologyChickenpoxbusiness.industryIncidence (epidemiology)immunization coverageHealth services researchUniversal Varicella VaccinationnotificationsVaricella; Universal Varicella Vaccination; Notifications; Hospitalizations; Immunization coverage; Adverse effectsmedicine.diseaseVaccinationImmunizationVaccination coverageUniversal Varicella Vaccination; Varicella; adverse events following varicella immunization; hospitalizations; immunization coverage; notificationsbusinesshospitalization
researchProduct